Safety, tolerability, pharmacokinetics and pharmacodynarnics of SK-0403, a novel DPP-IV inhibitor, in healthy Japanese subjects

被引：0
|
作者：
Sunami, Yukiko
Yoshioka, Naoya
Hayashi, Ichiro
Ishida, Tsutomu
Ishida, Tomu
机构：
来源：
DIABETES | 2007年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A128 / A129
页数：2
相关论文
共 50 条
  • [1] Characteristics and efficacy of SK-0403, a novel highly selective DPP-IV inhibitor, in animal models
    Goto, Moritaka
    Yasuda, Yoshika
    Nakaya, Keizo
    Kawamura, Satoko
    Kato, Noriaki
    Ishida, Tsutomu
    Matsumoto, Yukiharu
    DIABETES, 2007, 56 : A382 - A382
  • [2] The pharmacokinetics and pharmacodynamics of PF-00734200, a DPP-IV inhibitor, in healthy Japanese subjects
    Muto, Chieko
    Dai, Haiqing
    Teeter, John G.
    Johnson, Susan
    Cropp, Anne B.
    Chiba, Koji
    Suwa, Toshio
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2012, 50 (07) : 505 - 509
  • [3] Pharmacokinetics and Pharmacodynamics of PF-734200, a DPP-IV Inhibitor, in Healthy Japanese Subjects
    Dai, Haiqing
    Johnson, Susan L.
    Muto, Chieko
    Banerjee, Subhashis
    Yachi, Yasunori
    Nguyen, Tu T.
    Ghazzi, Mahmoud
    DIABETES, 2009, 58 : A534 - A534
  • [4] Pharmacokinetics and pharmacodynamics of SK-0403, a novel DPP-TV inhibitor, in rat:: IC80 for DPP-IV in circulation is insufficient to protect degradation of intact GLP-1
    Furuta, Shinji
    Goto, Moritaka
    Furuta, Yoshiyuki
    Yasuda, Yoshika
    Nakaya, Keizo
    Tamura, Miyuki
    Uesugi, Noriko
    Kawamura, Satoko
    Inoue, Akiharu
    Kato, Noriaki
    Ishida, Tsutomu
    Matsumoto, Yukiharu
    DIABETES, 2007, 56 : A382 - A382
  • [5] Effect of combination treatment with SK-0403, a highly selective DPP-IV inhibitor, and miglitol on incretin levels in obese and type 2 diabetic animals
    Goto, Moritaka
    Nakaya, Keizo
    Kawamura, Satoko
    Yasuda, Yoshika
    Kato, Noriaki
    Ishida, Tsutomu
    Matsumoto, Yuki-Haru
    DIABETES, 2008, 57 : A140 - A141
  • [6] A novel DPP-IV inhibitor ABT 279 is safe and effective in healthy overweight subjects
    Zhu, Tong
    Freeney, Tony A.
    Chiu, Yi-Lin
    Heuser, Kevin J.
    Pradhan, Rajendra J.
    Locke, Charles
    Awni, Walid M.
    Blakesley, Vicky A.
    DIABETES, 2007, 56 : A150 - A150
  • [7] Safety, tolerability, pharmacokinetics, & pharmacodynarnics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, in healthy male subjects: Multiple ascending dose study
    Kim, Dong-Kyu
    Lim, Kyoung Soo
    Cho, Joo-Youn
    Yu, Kyung-Sang
    Shin, Sang-Goo
    Kim, Sung-Ho
    Hwang, Dal-Mi
    Kwon, O. Hwan
    Lee, Sung-Hack
    Lee, Jaeick
    Kim, Jeong-Ae
    Jang, In-Jin
    Yim, Hyeon Joo
    DIABETES, 2008, 57 : A588 - A588
  • [8] Pharmacodynamic characteristics of SK-0403, a novel highly selective dipeptidyl peptidase IV inhibitor, in animal models
    Yasuda, Y.
    Goto, M.
    Nakaya, K.
    Kawamura, S.
    Furuta, S.
    Tamura, M.
    Kato, N.
    Ishida, T.
    Matsumoto, Y.
    DIABETOLOGIA, 2007, 50 : S284 - S284
  • [9] PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND TOLERABILITY OF A NOVEL FACTOR XIA INHIBITOR ADMINISTERED AS IV INFUSION IN NON-JAPANESE AND JAPANESE HEALTHY SUBJECTS.
    Perera, V.
    Frost, C. E.
    Yones, C. L.
    Wang, Z.
    Dorizio, S.
    Russo, C.
    Chen, W.
    Ueno, T.
    Akimoto, M.
    Cirincione, B.
    Xu, X.
    Seiffert, D. A.
    Desouza, M. M.
    Mugnier, P.
    LaCreta, F.
    Frost, R. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S42 - S42
  • [10] The Pharmacokinetics of PF-734200, a DPP-IV Inhibitor, in Subjects with Renal Insufficiency
    Dai, Haiqing
    Johnson, Susan L.
    Terra, Steven G.
    Mar-Bury, Thomas C.
    Smith, William B.
    Fuentes, Ernesto
    Alcorn, Harry
    Boyd, Rebecca
    Nguyen, Tu T.
    Ghazzi, Mahmoud
    DIABETES, 2009, 58 : A162 - A162
12345